David-Alexandre C. Gros, MD

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, also discussed other future plans for the company.

The chief executive officer of Eledon Pharmaceuticals also discussed other future plans for the company.

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.

The chief executive officer of Eledon Pharmaceuticals discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, discussed the company’s collaboration with EGenesis.

The chief executive officer of Eledon Pharmaceuticals discussed the company’s collaboration with EGenesis.